Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
108.2 USD | +0.10% | -1.97% | +68.89% |
Business Summary
- therapeutic products (99.9%);
- other (0.1%): cellular therapy products and biological materials for implants, for tissue and organ treatments, and for therapeutic product development.
Net sales are distributed geographically as follows: the United States (65.6%), Europe (24.7%) and other (9.7%).
Managers
Managers | Title | Age | Since |
---|---|---|---|
David Elkins
DFI | Director of Finance/CFO | 55 | 18-06-30 |
Matt Roden
PSD | President | 53 | 19-11-19 |
Director/Board Member | - | 19-11-19 | |
Director/Board Member | 48 | 19-11-19 | |
Timothy J. Smith
IRC | Investor Relations Contact | - | - |
Ann Li Lee
PRN | Corporate Officer/Principal | 63 | 18-02-28 |
Jeffrey Galik
TRE | Treasurer | - | 19-11-19 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Matt Roden
PSD | President | 53 | 19-11-19 |
Director/Board Member | 48 | 19-11-19 | |
Director/Board Member | - | 19-11-19 |
Company contact information
Group companies
Name | Category and Sector |
---|---|
Celgene International SARL
Celgene International SARL Pharmaceuticals: MajorHealth Technology Founded in 2010, Celgene International SARL is a Swiss bio-pharmaceutical company that operates to discover, develop, and commercialize therapies for unmet medical needs in cancer. Part of Bristol Myers Squibb Co., the private company is based in Boudry, Switzerland. |
Pharmaceuticals: Major
|
Celgene Logistics SARL
| |
Celgene International II SARL
| |
Seamair Insurance DAC
|
Sector
- Stock Market
- Equities
- CELG Stock
- Company Celgene